Abstract
Objective
The activity of the human cytochrome P450 and P-glycoprotein (P-gp) changes according to gender. The present study evaluated the effect of gender on the influence of carvedilol on serum digoxin levels in patients with heart failure.
Methods
Twenty-four patients (12 female and 12 male) with New York Heart Association class II-III heart failure were included in the study. Patients were taking oral digoxin (0.0625–0.25 mg, once a day) and were administered oral carvedilol (6.25 mg, two times daily) for 7 days.
Results
In the male group, carvedilol led to statistically significant increases in the area under the concentration time curve to 16 h (AUC0–16h) and the peak concentration (Cmax) for digoxin, with no change in time to peak (tmax)(AUC0–16h= 24.1±9.2 ng.h/ml vs. 15.4±5.8 ng.h/ml, p<0.001, Cmax=2.2±1.0 ng/ml vs. 1.6±0.6 ng/ml, p<0.01, tmax=2.4±2.2 h vs. 2.1±1.0 h, p>0.05). In the female group, carvedilol administration did not cause statistically significant change in the AUC0–16h, Cmax, or tmax for digoxin (p>0.05). In the male group, carvedilol resulted in a significant increase in the AUC0–16h and Cmax for digoxin compared with the female group (AUC0–16h=24.1± 9.2ng.h/ml vs. 17.0±6.8 ng.h/ml, Cmax=2.2±1.0 ng/ml vs. 1.5±0.6 ng/ml, p<0.05, respectively).
Conclusion
Men seem to have a higher activity relative to women for the drug efflux transporter P-gp. Our results suggest that carvedilol will cause drug interaction with digoxin following the inhibition of P-gp-mediated transcellular transport of digoxin in males.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aiba T, Ishida K, Yoshinaga M, Okuno M, Hashimoto Y (2005) Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers. Biol Pharm Bull 28:114–119
Bebia Z, Buch SC, Wilson JW, Frye FR, Romkes M, Ceccheti A, Chaves-Gnecco D, Branch RA (2004) Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 76:618–627
Cogan JJ, Humphreys MH, Carlson CJ, Benowitz NL, Rapaport E (1981) Acute vasodilator therapy increases renal clearance of digoxin in patients with congestive heart failure. Circulation 64:973–976
De Mey C, Brendel E, Enterling D (1990) Carvedilol increases the systemic bioavailability of oral digoxin. Br J Clin Pharmacol 29:486–490
Doering W (1983) Effect of coadministration of verapamil and quinidine on serum digoxin concentration. Eur J Clin Pharmacol 25:517–521
Gheorghiade M, Pitt B (1997) Digitalis Investigation Group (DIG) trial: a stimulus for further research. Am Heart J 134:3–12
Grunden JW, Gilbert EM, Munger MA (1994) Augmented digoxin concentrations with carvedilol dosing in mild-moderate heart failure. Am J Ther 1:157–161
Guven H, Tuncok Y, Guneri S, Cavdar C, Fowler J (1993) Age-related digoxin-alprazolam interaction. Clin Pharmacol Ther 54:42–44
Hagg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169–173
Kirimli O, Kalkan S, Güneri S, Tuncok Y, Akdeniz M, Ozdamar M, Guven H (2001) The effects of captopril on serum digoxin levels in patients with severe congestive heart failure. Int J Clin Pharmacol Ther 39:311–314
Labbe L, Sirois C, Pilote S, Arseneault M, Robitaille NM, Turgeon J, Hamelin BA (2000) Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10:425–438
Meibohm B, Bierle I, Derendorf H (2002) How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41:329–342
Ratnapalan S, Griffiths K, Costei AM, Benson L, Koren G (2003) Digoxin-carvedilol interactions in children. J Pediatr 142:572–574
Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K (2002) Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci 70:1491–1500
Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R (1992) Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263:840–845
The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525–533
Toto RD (1995) Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance. Curr Opin Nephrol Hypertens 4:505–509
Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R (1992) Human p-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone. J Biol Chem 267:24248–24252
Waldorff S, Andersen JD, Heeboll-Nielsen N et al (1978) Spironolactone-induced changes in digoxin kinetics. Clin Pharmacol Ther 24:162–167
Wermeling DP, Field CJ, Smith DA, Chandler MH, Clifton GD, Boyle DA (1994) Effects of long-term oral carvedilol on the steady-state pharmacokinetics of oral digoxin in patients with mild to moderate hypertension. Pharmacotherapy 14:600–606
Author information
Authors and Affiliations
Corresponding author
Additional information
The first two authors contributed equally.
Rights and permissions
About this article
Cite this article
Baris, N., Kalkan, S., Güneri, S. et al. Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference?. Eur J Clin Pharmacol 62, 535–538 (2006). https://doi.org/10.1007/s00228-006-0138-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-006-0138-7